TD Cowen raises Caris Life Sciences stock price target on pipeline

Caris Life Sciences shares fell 15% after market close despite Q3 sales beating expectations by 9% and improved full-year guidance; TD Cowen raised its price target to $38 from $36 and maintained a Buy rating. Q3 revenue rose 27% year over year to $275.4 million, but adjusted EPS of $0.05 missed the $0.16 estimate. Clinical sales were 14% ahead of estimates, largely on price increases, while clinical volume rose 21% year over year to 61,500 cases.

Analysis

The key issue is earnings quality, not demand alone: clinical revenue outperformance appears more price-led than volume-led, while the adjusted EPS miss suggests incremental sales are not yet translating into the profit investors expected. That combination can sustain growth but constrain multiple expansion until investors see durable volume gains and operating leverage. Pharma weakness also creates a mix risk: if research-service demand is less predictable, a strong clinical quarter may not reliably forecast consolidated results.

Near term, the sharp after-hours decline makes a reflexive bounce possible, but the prior run-up raises the bar for guidance to justify the valuation. Over the next 1–3 months, test whether clinical volumes continue to grow without further material price increases and whether margins or operating expenses explain the earnings gap. Over 6–18 months, the early pipeline could add value, but it is not yet a basis for underwriting near-term earnings.

The contrarian opportunity is that the selloff may over-penalize a temporary investment or expense issue; the counterpoint is that price-driven growth can mask weaker underlying demand. Verify the guidance increase, adjusted operating-expense trajectory, payer/pricing durability, and pharma bookings before assigning either interpretation. A continued volume slowdown, another earnings miss, or guidance rollback would falsify the constructive case.

Key Decisions for Investors

• Do not chase the post-earnings dip immediately. Treat CAI as a watch until the company clarifies the EPS shortfall and provides evidence that clinical growth is not predominantly dependent on pricing.
• Consider a staged long only if subsequent disclosures show sustained clinical-volume growth alongside improving operating leverage; define the thesis failure as a guidance reduction or another adjusted-earnings miss.
• For a near-term risk position, use a defined-risk bearish structure rather than an outright short after a 15% after-hours decline; the move may already reflect much of the earnings disappointment. Reassess after management commentary and regular-session price discovery.
• Track pharma-service bookings, clinical volume, realized pricing, and operating expenses at the next update. If pricing rises while volume decelerates and profit conversion remains weak, the premium-growth thesis is vulnerable; if volume and margins strengthen together, the selloff may be excessive.